KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Gold Prices Slip From 10-Week High as Fed and Hormuz Risks Shape Outlook 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Strait of Hormuz Shipping Near Standstill After New Vessel Attacks 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious 
Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
Add as a preferred source on Google
NGeneBio, a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx) in South Korea, announced it had established its new subsidiary in the United States. The company said on Monday, July 24, it has set up an artificial intelligence (AI) precision diagnostic firm called NGeneBioAI.
NGeneBio formed this company to tap into the U.S. precision diagnosis market. The plan is to earmark the data-driven cancer genomic diagnostics market in the country through its own precision diagnostic software.
According to The Korea Economic Daily, the formation of NGeneBioAI was fully funded by NGeneBio, which is now standing as its parent company. Its US subsidiary is now expected to play a big role in NGeneBio’s entry into the region’s cancer diagnostics market. It will offer its next-generation sequencing (NGS) precision diagnostic platform as it starts to build its presence in the American market.
Moreover, in addition to services related to cancer data analysis, NGeneBio will also initiate healthcare data analysis technology. The company will create AI-based diagnostic software with the aim of commercializing data-driven early cancer diagnosis apparatus.
“NGENBIO’s precise diagnosis SW technology is being evaluated as excellent in performance and quality by clinicians to the extent that it is being used in clinical trials for cancer patients at domestic and foreign medical institutions,” NGeneBio’s chief executive officer, Choi Dae Chul explained in a press release.
The CEO added, “With the establishment of NGENBIO AI, we will increase the accuracy of cancer precision diagnosis by expanding NGENBIO SW to the US medical market, and speed up the ongoing strategic investment in the CLIA Lab to complete within the year.”
Finally, Korea Biomedical Review reported that the supply of the company’s NGS precision diagnosis product line will also start in earnest via partnership deals with Clinical Laboratory Improvement Amendments (CLIA) Labs in the U.S.
Photo by: NGeneBio Website
